Semantic Scholar uses AI to extract papers important to this topic.
To evaluate CAT-152 (lerdelimumab), a monoclonal antibody to transforming growth factor-beta2 (TGF-beta2), in… Expand PURPOSE
Inhibition of TGF-beta reduces myofibroblast differentiation and fibrosis in the cornea. Determining the actions of… Expand Transforming growth factor beta (TGFbeta), a potent inducer of cell transdifferentiation, is heavily implicated in fibrotic… Expand There is increasing evidence implicating Transforming growth factor beta (TGF-beta) in pathological states of the lens. However… Expand Purpose of review This paper summarizes the use of antifibrotic agents adjunctive to glaucoma surgery, reviews recently published… Expand PURPOSE
Postoperative subconjunctival wound healing remains the commonest cause of late bleb failure after glaucoma filtration… Expand PURPOSE
To study the role of TGF-beta2 in posterior capsule opacification (PCO) and to determine whether CAT-152 (lerdelimumab… Expand PURPOSE
The human monoclonal antibody that neutralizes the growth factor TGFbeta(2) (CAT-152) safely and effectively inhibits in… Expand Norwich, England-A human monoclonal antibody, CAT-152, may help aid bleb survival in patients with primary open-angle glaucoma… Expand Diabetic nephropathy is characterised by an increase in glomerular and tubular fibrosis that compromises kidney function. The… Expand